Anti-Claudin Antibodies as a Concept for Development of Claudin-Directed Drugs.

Amino Acid Sequence Animals Autoantibodies / genetics Claudins / antagonists & inhibitors Drug Development / trends Humans Pharmaceutical Preparations / metabolism

Journal

The Journal of pharmacology and experimental therapeutics
ISSN: 1521-0103
Titre abrégé: J Pharmacol Exp Ther
Pays: United States
ID NLM: 0376362

Informations de publication

Date de publication:
02 2019
Historique:
received: 08 08 2018
accepted: 06 12 2018
pubmed: 12 12 2018
medline: 5 11 2019
entrez: 12 12 2018
Statut: ppublish

Résumé

Claudin (CLDN) proteins, a tetra-transmembrane family containing over 20 members, have been identified as key structural and functional components of intercellular seals, tight junctions (TJs). CLDNs are involved in the barrier and fence functions of TJs. Loosening the TJ barrier is one strategy for increasing drug absorption and delivery to the brain. Due to aberrant CLDN expression, the TJ fence function is frequently dysregulated in carcinogenesis. In addition, CLDN-1 is a co-receptor for the hepatitis C virus. Together these characteristics indicate CLDNs as promising targets for drug development, and CLDN binders are potential candidates for delivering drugs, treating cancer, and preventing viral infection. Before 2008, a receptor-binding fragment of

Identifiants

DOI: 10.1124/jpet.118.252361 PMID: 30530622
pubmed: 30530622
pii: jpet.118.252361
doi: 10.1124/jpet.118.252361
doi:

Substances chimiques

Autoantibodies 0
Claudins 0
Pharmaceutical Preparations 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

179-186

Informations de copyright

Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics.

Auteurs

Yosuke Hashimoto (Y)

Research Institute of Environmental Medicine, Nagoya University, Aichi, Japan (Y.H., M.S.) and Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan (Y.O., K.S., K.T., K.Y., T.D., M.K.).

Yoshiaki Okada (Y)

Research Institute of Environmental Medicine, Nagoya University, Aichi, Japan (Y.H., M.S.) and Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan (Y.O., K.S., K.T., K.Y., T.D., M.K.).

Keisuke Shirakura (K)

Research Institute of Environmental Medicine, Nagoya University, Aichi, Japan (Y.H., M.S.) and Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan (Y.O., K.S., K.T., K.Y., T.D., M.K.).

Keisuke Tachibana (K)

Research Institute of Environmental Medicine, Nagoya University, Aichi, Japan (Y.H., M.S.) and Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan (Y.O., K.S., K.T., K.Y., T.D., M.K.).

Makoto Sawada (M)

Research Institute of Environmental Medicine, Nagoya University, Aichi, Japan (Y.H., M.S.) and Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan (Y.O., K.S., K.T., K.Y., T.D., M.K.).

Kiyohito Yagi (K)

Research Institute of Environmental Medicine, Nagoya University, Aichi, Japan (Y.H., M.S.) and Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan (Y.O., K.S., K.T., K.Y., T.D., M.K.).

Takefumi Doi (T)

Research Institute of Environmental Medicine, Nagoya University, Aichi, Japan (Y.H., M.S.) and Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan (Y.O., K.S., K.T., K.Y., T.D., M.K.).

Masuo Kondoh (M)

Research Institute of Environmental Medicine, Nagoya University, Aichi, Japan (Y.H., M.S.) and Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan (Y.O., K.S., K.T., K.Y., T.D., M.K.) masuo@phs.osaka-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Sciences de l'information › Sources d'information › Services d'information › Documentation › Données de séquences moléculaires › Séquence d'acides aminés › Anti-Claudin Antibodies as a Concept for...
questionsmedicales.fr › Eucaryotes › Animaux › Anti-Claudin Antibodies as a Concept for...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Autoanticorps › Anti-Claudin Antibodies as a Concept for...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Protéines de la jonction serrée › Claudines › Anti-Claudin Antibodies as a Concept for...
questionsmedicales.fr › Techniques d'investigation › Développement de médicament › Anti-Claudin Antibodies as a Concept for...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Anti-Claudin Antibodies as a Concept for...
questionsmedicales.fr › Préparations pharmaceutiques › Anti-Claudin Antibodies as a Concept for...